John C. Fortson
Known title: EVP & CFOCIK: 0001582539
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Ingevity sets Q3 2026 earnings date; article discusses holding reasons. Ingevity announced the dates for its third‑quarter 2026 earnings release and the accompanying webcast. A recent Yahoo article outlined several points that investors have cited for maintaining their positions in the company. The upcoming earnings call may provide additional data that could influence market views.
Transaction History
| XRAY | ▲ Buy | Grant | 24,014 | $0 | 8/10/2026 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 1,597 | $72K | 2/28/2024 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 2,995 | $136K | 2/28/2024 | View on chart |
| NGVT | ▲ Buy | Grant | 15,107 | $0 | 2/28/2024 | View on chart |
| NGVT | ▲ Buy | Grant | 35,344 | $0 | 2/28/2024 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 1,377 | $66K | 2/26/2024 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 5,527 | $262K | 2/22/2024 | View on chart |
| NGVT | ▲ Buy | Grant | 11,934 | $0 | 2/22/2024 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 803 | $66K | 2/28/2023 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 1,597 | $132K | 2/28/2023 | View on chart |
| NGVT | ▲ Buy | Grant | 19,380 | $0 | 2/28/2023 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 1,376 | $121K | 2/27/2023 | View on chart |
| NGVT | ▲ Buy | Grant | 8,835 | $0 | 2/16/2023 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 2,810 | $252K | 2/16/2023 | View on chart |
| NGVT | ▲ Buy | Grant | 10,430 | $0 | 2/16/2023 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 3,270 | $293K | 2/16/2023 | View on chart |
| NGVT | ▲ Buy | Grant | 10,333 | $0 | 2/28/2022 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 305 | $21K | 2/28/2022 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 3,018 | $206K | 2/28/2022 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 803 | $55K | 2/28/2022 | View on chart |
| NGVT | ▼ Sell | Tax Withholding | 1,371 | $94K | 2/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage
XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.